| 赵宇晗,王兆亿,李 娜,张孟姣,王慧娟.当归明目汤联合球内注药阿柏西普治疗对年龄相关性黄斑变性患者眼压、视网膜厚度的影响[J].现代生物医学进展英文版,2024,(6):1100-1104. |
| 当归明目汤联合球内注药阿柏西普治疗对年龄相关性黄斑变性患者眼压、视网膜厚度的影响 |
| Effect of Danggui Mingmu Decoction Combined with Intravitreal Injection of Aflibercept on Intraocular Pressure and Retinal Thickness in Patients with Age-related Macular Degeneration |
| Received:September 08, 2023 Revised:September 30, 2023 |
| DOI：10.13241/j.cnki.pmb.2024.06.018 |
| 中文关键词: 年龄相关性黄斑变性 当归明目汤 球内注药阿柏西普 眼压 视网膜厚度 |
| 英文关键词: Age-related macular degeneration Danggui Mingmu Decoction Intraocular injection of aflibercept Intraocular pressure Retinal thickness |
| 基金项目:首都卫生发展科研专项项目（首发2020-2-4182） |
|
| Hits: 327 |
| Download times: 228 |
| 中文摘要: |
| 摘要 目的：分析当归明目汤联合球内注药阿柏西普治疗对年龄相关性黄斑变性（AMD）患者眼压、视网膜厚度的影响。方法：回顾性分析2022年2月～2023年2月本院收治的80例AMD患者的临床资料，根据治疗方法将其分为对照组和观察组，每组各40例，对照组给予球内注药阿柏西普治疗，观察组在对照组的基础上联合当归明目汤治疗。观察两组患者治疗前及治疗1周、1个月、3个月后的眼压、黄斑中心凹视网膜厚度（CRT）、黄斑中心凹旁厚度（PMT）、黄斑中心凹血流密度、黄斑中心凹旁血流密度、最佳矫正视力（BCVA）和脉络新生血管（CNV）面积水平。结果：治疗1周、1个月、3个月后，两组眼压均低于治疗前，观察组眼压均低于对照组（P＜0.05）。治疗后，与对照组比较，观察组CRT、黄斑中心凹旁厚度、黄斑中心凹血流密度较低（P＜0.05）。治疗1周、1个月、3个月后，两组BCVA水平较低于治疗前，观察组BCVA水平较低于对照组（P＜0.05）。与治疗前比较，两组治疗1周、1个月、3个月后CNV面积较低（P＜0.05）。结论：当归明目汤联合球内注药阿柏西普治疗有利于稳定AMD患者的眼压，并降低黄斑区血管密度和视网膜厚度，同时还能在一定程度上改善患者的视力。 |
| 英文摘要: |
| ABSTRACT Objective: To analyze the effect of Danggui Mingmu Decoction combined with intravitreal injection of aflibercept on intraocular pressure and retinal thickness in patients with age-related macular degeneration (AMD). Methods: The clinical data of 80 AMD patients admitted to our hospital from February 2022 to February 2023 were retrospectively analyzed, and they were divided into control group and observation group according to the treatment methods. In each group, 40 cases, the control group were given intrabulbar injection abercept, and the observation group was treated with Angelica Mingmu Decoction on the basis of the control group. IOP, macular foveal retinal thickness (CRT), parfoveal thickness (PMT), macular foveal blood flow density, parfoveal blood flow density, best corrected visual acuity (BCVA), and choroidal neovascular (CNV) area levels before and 1 week, 1 month, and 3 months after treatment. Results: After 1 week, 1 month and 3 months of treatment, the intraocular pressure of the two groups was lower than that before treatment, and the intraocular pressure of the observation group was lower than that of the control group (P<0.05). After treatment, compared with the control group, the CRT, macular foveal thickness and macular foveal blood flow density in the observation group were lower (P <0.05). After 1 week, 1 month and 3 months of treatment, the BCVA levels of the two groups were lower than those before treatment, and the BCVA level of the observation group was lower than that of the control group(P<0.05). Compared with before treatment, the CNV area of the two groups was lower after 1 week, 1 month and 3 months of treatment (P<0.05). Conclusion: Danggui Mingmu Decoction combined with intravitreal injection of aflibercept is beneficial to stabilize the intraocular pressure of AMD patients, reduce the vascular density and retinal thickness in macular area, and improve the visual acuity of patients to a certain extent. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
